Stata Modules for Calculating Novel Predictive Performance Indices for Logistic Models

Authors Information
Article Notes and Dates
To Cite : Barkhordari M, Padyab M, Hadaegh F, Azizi F, Bozorgmanesh M. et al. Stata Modules for Calculating Novel Predictive Performance Indices for Logistic Models, Int J Endocrinol Metab. 2016 ;14(1):e59235. doi: 10.5812/ijem.26707.
Copyright: Copyright © 2016, International Journal of Endocrinology and Metabolism. .
Abstract
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol. 2011; 173(11): 1327-35[DOI][PubMed]
  • 2. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27(2): 157-72[DOI][PubMed]
  • 3. Yadegari H, Bozorgmanesh M, Hadaegh F, Azizi F. Non-linear contribution of glucose measures to cardiovascular diseases and mortality: reclassifying the Framingham's risk categories: a decade follow-up from the Tehran lipid and glucose study. Int J Cardiol. 2013; 167(4): 1486-94[DOI][PubMed]
  • 4. Wilson PW, D'Agostino R. Sr., Bhatt DL, Eagle K, Pencina MJ, Smith SC, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012; 125(7): 695-703 e1[DOI][PubMed]
  • 5. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. 2009;
  • 6. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007; 115(7): 928-35[DOI][PubMed]
  • 7. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem. 2008; 54(1): 17-23[DOI][PubMed]
  • 8. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006; 145(1): 21-9[PubMed]
  • 9. Cook NR, Paynter NP. Performance of reclassification statistics in comparing risk prediction models. Biom J. 2011; 53(2): 237-58[DOI][PubMed]
  • 10. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol. 2009; 54(14): 1209-27[DOI][PubMed]
  • 11. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med. 2010; 48(12): 1703-11[DOI][PubMed]
  • 12. Polak JF, Meisner A, Pencina MJ, Wolf PA, D'Agostino RB. Variations in common carotid artery intima-media thickness during the cardiac cycle: implications for cardiovascular risk assessment. J Am Soc Echocardiogr. 2012; 25(9): 1023-8[DOI][PubMed]
  • 13. Caputo RP, Goel A, Pencina M, Cohen DJ, Kleiman NS, Yen CH, et al. Impact of drug eluting stent length on outcomes of percutaneous coronary intervention (from the EVENT registry). Am J Cardiol. 2012; 110(3): 350-5[DOI][PubMed]
  • 14. Pencina MJ, D'Agostino RB. Sr., Song L. Quantifying discrimination of Framingham risk functions with different survival C statistics. Stat Med. 2012; 31(15): 1543-53[DOI][PubMed]
  • 15. Novack V, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Saucedo JF, et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med. 2012; 172(6): 502-8[DOI][PubMed]
  • 16. Widera C, Pencina MJ, Meisner A, Kempf T, Bethmann K, Marquardt I, et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur Heart J. 2012; 33(9): 1095-104[DOI][PubMed]
  • 17. Pencina MJ, D'Agostino RB. Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011; 30(1): 11-21[DOI][PubMed]
  • 18. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009; 10: 5[DOI][PubMed]
  • 19. Bozorgmanesh M, Hadaegh F, Azizi F. Predictive accuracy of the 'Framingham's general CVD algorithm' in a Middle Eastern population: Tehran Lipid and Glucose Study. Int J Clin Pract. 2011; 65(3): 264-73[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

International Journal of Endocrinology and Metabolism accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check